加载中
NASDAQHealthcareBiotechnology
最新数据
US$35.93
−US$1.29 · -3.47%
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
收盘时
US$35.93
−US$1.29 · -3.47%
盘后
US$35.93
US$0.00 · 0.00%
10月12日 16:12 ET
盘中时间采用ET。市场数据可能有所延迟。
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
日内区间
当前US$35.93
52周区间
当前US$35.93
盘中时间采用ET。市场数据可能有所延迟。
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
日内区间
当前US$35.93
52周区间
当前US$35.93
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 研究与开发 | 1674.4万 USD | 5117.1万 USD | 784.5万 USD | 134.6万 USD |
| 销售、一般及管理费用 | 1366万 USD | 1365.9万 USD | 353.1万 USD | 146.3万 USD |
| 营业费用 | 3040.4万 USD | 6483万 USD | 1137.6万 USD | 280.9万 USD |
| 利息收入 | 392万 USD | 172.1万 USD | 81.1万 USD | 7.3万 USD |
| 利息支出 | — | — | 482.5万 USD | 215.1万 USD |
| 折旧和摊销 | 32.1万 USD | 9.1万 USD | 4000 USD | 2000 USD |
| 营业利润 | −3040.4万 USD | −6483万 USD | −1137.6万 USD | −280.9万 USD |
| 净利润 | −2520.5万 USD | −6310.2万 USD | −627.5万 USD | −1434.8万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3232.63万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2183.37万0.03%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1336.91万0.01%954亿 USD0.05%US$233.52-0.63%
State Street SPDR S&P Pharmaceuticals ETFXPH621.03万1.35%4.62亿 USD0.35%US$64.01-0.99%
Vanguard Russell 2000 ETFVTWO607.49万0.03%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA498.2万0.02%218.24亿 USD0.03%US$32.66-0.40%
iShares Russell 2000 Growth ETFIWO369.72万0.03%139.17亿 USD0.24%US$353.71-0.86%
iShares U.S. Pharmaceuticals ETFIHE326.17万0.21%15.52亿 USD0.37%US$100.19+0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares U.S. Pharmaceuticals ETFIHEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
